Bullous Pemphigoid (BP) is an acquired, rare autoimmune skin disorder.&nbsp;It is a subepidermal bullous disease where autoantibodies are directed against the skin’s basement membrane zone components.&nbsp; Bullous Pemphigoid Epidemiological Segmentation&nbsp; The Epidemiological Segmentation of Bullous Pemphigoid in the 7MM from 2018 to 2030 is segmented into:- <ul><li>Diagnosed Prevalent cases of Bullous Pemphigoid</li><li>Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid</li><li>Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid</li><li>Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid</li></ul> <a href="https://www.delveinsight.com/report-store/bullous-pemphigoid-epidemiology-forecast" rel="noopener noreferrer" target="_blank" style="color: rgb(0, 71, 178); background-color: transparent;">Bullous Pemphigoid Epidemiological Insights</a> Observed in 2020 <ul><li>The total diagnosed prevalent cases of Bullous Pemphigoid in 7MM were found to be 124,517.</li><li>The diagnosed prevalent cases of Bullous Pemphigoid in the United Kingdom were observed to be 24,644.</li><li>The diagnosed prevalent cases of Bullous Pemphigoid in France were 23,843.</li><li>The diagnosed prevalent cases of Bullous Pemphigoid in Germany were found to be 17,626.</li><li>The diagnosed prevalent cases of Bullous Pemphigoid in Spain were observed to be 10,920.</li><li>The diagnosed prevalent cases of Bullous Pemphigoid Japan were observed to be 8,619.</li><li>In the United States, the Age-specific Diagnosed Prevalent cases of Bullous Pemphigoid in males were found to be 11,018, whereas in females, it was observed to be 14,023.</li></ul> <a href="https://www.delveinsight.com/report-store/bullous-pemphigoid-market" rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204); background-color: transparent;">Bullous Pemphigoid Market</a> The market size of Bullous Pemphigoid in the 7MM was found to be USD 151 Million in 2020. Bullous Pemphigoid Market Drivers<ul><li>Robust emerging pipeline</li><li>Ubiquitous prevalence</li><li>Precise diagnostic procedures&nbsp;</li></ul> Bullous Pemphigoid Market Barriers<ul><li>Complications associated with available therapies</li><li>Delayed diagnosis</li><li>Polypharmacy</li><li>Lack of disease awareness&nbsp;</li></ul> <a href="https://www.delveinsight.com/report-store/bullous-pemphigoid-pipeline-insight" rel="noopener noreferrer" target="_blank" style="color: rgb(0, 71, 178); background-color: transparent;">Bullous Pemphigoid Emerging Drugs</a> The emerging drugs of the Bullous Pemphigoid market are <ul><li>Dupilumab (Dupixent)</li><li>Nomacopan (rVA576, Coversin)</li><li>iCo-008 (Bertilimumab)</li><li>Avdoralimab (IPH5401)</li><li>Fasenra (benralizumab)</li><li>AKST4290, and others</li></ul> Bullous Pemphigoid Key Players The key players working in the Bullous Pemphigoid market are&nbsp; <ul><li>Regeneron Pharmaceuticals</li><li>Sanofi</li><li>Akari Therapeutics</li><li>Immune Pharmaceuticals</li><li>iCo Therapeutics</li><li>Innate Pharma</li><li>AstraZeneca</li><li>Alkahest Inc.</li><li>Grifols, and others</li></ul>

Bullous Pemphigoid Market

Bullous Pemphigoid Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape